06:06 AM EDT, 08/28/2026 (MT Newswires) -- The US Patent and Trademark Office granted a notice of allowance to Elicera Therapeutics' (ELIC.ST) patent application for ELC-401, its CAR T-cell candidate against glioblastoma. The intellectual property rights application aims to protect the special antibodies that recognize and bind to the protein IL-13Ra2, which is often present in cancer cells, as well as their use in cancer treatment, the clinical-stage cell and gene therapy company said Friday. The patent gives Elicera the exclusive rights to develop and market anti-IL-13Ra2 antibody therapies and related cancer treatment technologies in the US.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.